A phase III trial evaluating the role of exemestane plus GnRH analogue as adjuvant therapy for premenopausal women with endocrine responsive breast cancer

Tamoxifen and Exemestane Trial (TEXT)

Study Chairs
BIG: Dr. Olivia Pagani - Mendrisio, Switzerland
US Intergroup: Dr. Barbara Walley - Calgary, Canada

Statistician
Dr. Meredith Regan

Lead Trial Coordinator
Holly Shaw

Data Managers
Monica Greco, Adriana Mora de Karausch


IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Date of Activation
August 4, 2003

Date of Closure
March 11, 2011

Targeted Accrual
2639 patients

Final Accrual
2672 patients

International Breast
Cancer Study Group

Effingerstrasse 40
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: ibcsgcc@ibcsg.org

Member Login